The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 18, 2021

Filed:

Mar. 26, 2019
Applicant:

The Government of the United States of America, As Represented BY the Secretary of Homeland Security, Washington, DC (US);

Inventors:

Michael Puckette, Waterford, CT (US);

Max Rasmussen, Guilford, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 9/50 (2006.01); A61K 39/12 (2006.01); C12N 9/96 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/96 (2013.01); A61K 39/12 (2013.01); A61P 31/14 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 9/506 (2013.01); C12Y 304/22044 (2013.01); A61K 2039/523 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5258 (2013.01); C12N 2770/32122 (2013.01); C12N 2770/32123 (2013.01); C12N 2770/32134 (2013.01); C12N 2770/32151 (2013.01);
Abstract

Polynucleotide constructs that express an engineered foot-and-mouth disease (FMDV) P1 precursor protein and a non-FMDV TEV protease and methods for safe and efficient recombinant production of FMDV antigens and immunogens. Recombinant production of FMDV antigens avoids the need to culture highly-infectious FMDV, while conventional culture methods for producing FMDV antigens rely on the native FMDV 3C protease which exerts toxic effects on host cells. The inventors have developed a new system that efficiently and safely processes FMDV P1 precursor without the FMDV 3C protease, thus avoiding the toxic effects associated with use of the 3C protease. The invention is also directed to the FMDV antigens and virus-like particles produced by this system as well as to FMDV vaccines, diagnostics and other biologics.


Find Patent Forward Citations

Loading…